Prevention of Kidney Injury Associated With Brain Death
Conditions
Keywords
Thymoglobulin, Cadaver donor, Kidney injury brain death related
Brief summary
To determine the efficacy and Security of Thymoglobuline in cadaveric donor Efficacy: To demonstrate that in cadaveric donor, Thymoglobuline diminished graft alloreactivity by decreasing expression of inflammatory markers in graft biopsies Security:To demonstrate that the administration of Thymoglobulin does not have side effects in renal recipients.
Detailed description
This is randomized controlled Multicenter phase II clinical trial promoted by members from IdiPAZ. At least two hospital (La Paz and Santa Maria from Lisbon, will be involved. A per nature pilot study will recruit 10 cadaver donors from each hospital, and randomized half-to-half per center, for study and control groups. The RCT initiated in 2009 and finished in 2013. Cadaver donor from the study group will receive 3 mg/kg iv. Thymoglobulin 3-6 hours prior to organ procurement. The randomization process recruits 1:1 study/control donors. Kidney biopsies will be taken from each kidney before transplantation to examine the expression of pro-inflammatory and HLA molecules (anti-DR, VCAM, ICAM, E-selectin) at tubular cells by immunohistochemical techniques under blinded conditions. Recipients will be managed as usual and expressly followed up for one year, recording the incidence of delayed graft function and rejection and graft survival at the first year. A comparison between the results obtained in kidney biopsies and patients transplanted in each group will permit differentiate whether Thymoglobulin administered in cadaver modifies the expression of antigens by kidney tubular cells and the results obtained with transplantation, in terms of graft function, rejection and survival.
Interventions
DRUGThymoglobulin
Sponsors
Hospital de Santa Maria, Portugal
Instituto de Investigación Hospital Universitario La Paz
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Accepted adults cadaveric donors for renal transplant from University Hospital La Paz( Madrid) and from University Hospital Santa Maria (Lisbon) * Informed consent from relatives for including in the study
Exclusion criteria
* Known allergy to the rabbit proteins * Non accepted grafts * Family refusal to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Thymoglobuline in cadaveric donor | 2 days | To determine the efficacy of Thymoglobuline in cadaveric donor Efficacy: To demonstrate that in cadaveric donor, Thymoglobuline diminished graft alloreactivity by decreasing expression of inflammatory markers(determining HLA-DR,VCAM-1, ICAM-1 expressions by immunohistochemistry in graft biopsies), and the rates of delayed graft function and cellular/humoral rejection demonstrated by biopsy. |
| Security of Thymoglobuline in cadaveric donor | 1 day | Estimated by general and particularly hemodynamic tolerance to thymoglobulin infusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of acute rejection in the recipients | 3 moths | To demonstrate that in cadaveric donors, Thymoglobuline tends to decrease the incidence of acute rejection demonstrated by kidney biopsy. |
| Incidence of delayed graft function in the recipients. | 1 month | To demonstrate that in cadaveric donors, Thymoglobuline tends to decrease the incidence of DGF estimated by the necessity of dialysis after transplantation. |
| Composite of incidence of graft function and general effects in the recipients. | 1 year | To demonstrate that Thymoglobuline administered in cadaveric donors does not have neither repercussion on graft function nor side effects in renal and liver recipients. |
Countries
Portugal, Spain
Outcome results
None listed